blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4289432

EP4289432 - PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVE [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  10.11.2023
Database last updated on 09.04.2026
FormerThe international publication has been made
Status updated on  03.03.2023
Most recent event   Tooltip07.10.2025New entry: Renewal fee paid 
Applicant(s)For all designated states
Shionogi & Co., Ltd
1-8, Doshomachi 3-chome
Chuo-ku
Osaka-shi, Osaka 541-0045 / JP
[2023/50]
Inventor(s)01 / GOMI Masato
Osaka-shi, Osaka 541-0045 / JP
02 / HORIUCHI Kensuke
Osaka-shi, Osaka 541-0045 / JP
03 / MORIMOTO Masayuki
Osaka-shi, Osaka 541-0045 / JP
04 / TAKAGAKI Keisuke
Osaka-shi, Osaka 541-0045 / JP
 [2023/50]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2023/50]
Application number, filing date22861484.822.11.2022
[2023/50]
WO2022JP43092
Priority number, dateJP2021018993224.11.2021         Original published format: JP 2021189932
JP2021019163526.11.2021         Original published format: JP 2021191635
JP2022000672519.01.2022         Original published format: JP 2022006725
JP2022001238628.01.2022         Original published format: JP 2022012386
JP2022001713207.02.2022         Original published format: JP 2022017132
JP2022002762925.02.2022         Original published format: JP 2022027629
JP2022004630423.03.2022         Original published format: JP 2022046304
JP2022014276708.09.2022         Original published format: JP 2022142767
CN20221115179121.09.2022         Original published format: CN202211151791
[2023/50]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2023027198
Date:02.03.2023
Language:JA
[2023/09]
Type: A1 Application with search report 
No.:EP4289432
Date:13.12.2023
Language:EN
[2023/50]
Search report(s)International search report - published on:JP02.03.2023
(Supplementary) European search report - dispatched on:EP18.12.2024
ClassificationIPC:A61K31/53, A61K9/20, A61K31/194, A61K47/32, A61K47/38, A61P11/00, A61P31/12, A61P31/14, A61P43/00, C07D403/14
[2023/50]
CPC:
A61K9/2027 (EP,KR); A61K31/53 (EP,KR,US); A61K31/194 (EP,KR);
A61K9/1623 (US); A61K9/1652 (US); A61K9/2018 (US);
A61K9/2054 (EP,KR,US); A61P31/14 (KR); C07D403/14 (EP) (-)
C-Set:
A61K31/194, A61K2300/00 (EP);
A61K31/53, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   ME,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/50]
TitleGerman:TRIAZINDERIVATE ENTHALTENDE ZUBEREITUNG ZUR ORALEN VERABREICHUNG[2023/50]
English:PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVE[2023/50]
French:PRÉPARATION POUR ADMINISTRATION ORALE CONTENANT UN DÉRIVÉ DE TRIAZINE[2023/50]
Entry into regional phase07.09.2023Translation filed 
07.09.2023National basic fee paid 
07.09.2023Search fee paid 
07.09.2023Designation fee(s) paid 
07.09.2023Examination fee paid 
Examination procedure07.09.2023Examination requested  [2023/50]
26.06.2025Amendment by applicant (claims and/or description)
26.06.2025Date on which the examining division has become responsible
Fees paidRenewal fee
04.10.2024Renewal fee patent year 03
06.10.2025Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[E] EP4122926  (SHIONOGI & CO et al.) [E] 1,12,13 * claims 1-36 *
 [A] EP2399910  (SHIONOGI & CO et al.) [A] 1-16 * claims 1-22 *
 [A]   OLUBIYI OLUJIDE O. ET AL: "High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2", MOLECULES, vol. 25, no. 14, 13 July 2020 (2020-07-13), pages 3193, XP055944494, DOI: 10.3390/molecules25143193 [A] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.3390/molecules25143193
International search[P, X] WO2022138988  (SHIONOGI & CO et al.) [P, X] 1-5 * claims, examples *
 [A] WO2012020749  (SHIONOGI & CO et al.) [A] 1-5 * claims, examples *
 [A] WO2010092966  (SHIONOGI & CO et al.) [A] 1-5 * claims, examples *
 [P, X]   UNOH YUTO, UNOH YUTO, UEHARA SHOTA, NAKAHARA KENJI, NOBORI HARUAKI, YAMATSU YUKIKO, YAMAMOTO SHIHO, MARUYAMA YUKI, TAODA YOSHIYUKI: "Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 65, no. 9, 12 May 2022 (2022-05-12), US , pages 6499 - 6512, XP093007183, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.2c00117 [P, X] 1-5 * abstract *

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.2c00117
 [A]   OLUBIYI OLUJIDE O., OLAGUNJU MARYAM, KEUTMANN MONIKA, LOSCHWITZ JENNIFER, STRODEL BIRGIT: "High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2", MOLECULES, vol. 25, no. 14, pages 3193, XP055944494, DOI: 10.3390/molecules25143193 [A] 1-5 * entire text *

DOI:   http://dx.doi.org/10.3390/molecules25143193
 [A]   AKAJI KENICHI, KONNO HIROYUKI: "Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease", MOLECULES, vol. 25, no. 17, pages 3920, XP055826867, DOI: 10.3390/molecules25173920 [A] 1-5 * entire text *

DOI:   http://dx.doi.org/10.3390/molecules25173920
 [A]   LIU YUZHI; LIANG CHENGYUAN; XIN LIANG; REN XIAODONG; TIAN LEI; JU XINGKE; LI HAN; WANG YONGBO; ZHAO QIANQIAN; LIU HONG; CAO WENQIA: "The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 206, 6 August 2020 (2020-08-06), AMSTERDAM, NL , XP086299093, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2020.112711 [A] 1-5 * entire text *

DOI:   http://dx.doi.org/10.1016/j.ejmech.2020.112711
by applicantWO2012020749
 WO2013089212
 WO2010092966
 WO2014200078
 WO2012009258
 WO2021205298
 WO2021250648
 CN113620888
 CN113666914
 CN113735838
 CN113773300
 CN113801097
   "COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University", 21 September 2022, JOHNS HOPKINS UNIVERSITY
   THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 382, 2020, pages 1564 - 1567
   "Report of the WHO-China Joint Mission on Coronavirus disease 2019 (COVID-19", 28 February 2020, WHO
   SCIENCE, vol. 300, 2003, pages 1763 - 1767
   "A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF'-00835231 as a potential new treatment for COVID-l_9", JOURNAL OF VIROLOGY, 26 April 2021 (2021-04-26), Retrieved from the Internet
   CELL RESEARCH, vol. 30, 2020, pages 678 - 692
   SCIENCE, vol. 368, 2020, pages 409 - 412
   A(S CENTRAL SCIENCE, vol. 7, no. 3, 2021
   CANCER TREATMENT REVIEWS, vol. 11, 1984, pages 99 - 110
   CONTRIBUTIONS TO ONCOLOGY, vol. 18, 1984
   ARZNEIMITTEL-FORSCLMNG, vol. 6, 1984, pages 663 - 668
   261ST AM CHEM SOC (ACS) NATL MEET, 5 April 2021 (2021-04-05)
   SCIENCE, vol. 374, 2021, pages 1586 - 1593
   "Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89,% In Interim Analysis Of Phase 2/3 EPIC-HR Study", 5 November 2021, PFIZER PRESS RELEASE
   AIMECS 2021 (AFMC INTERNATIONAL MEDICINAL CHEMISTRY SYMPOSIUM 2021, 2 December 2021 (2021-12-02)
   "Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19", BIORXIV, Retrieved from the Internet
   "Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19", J. MED. CHEM., vol. 65, 2022, pages 6499 - 6512
   "Isotopes in the Physical and Biomedical Sciences", vol. 1, 1987, article "Labeled Compounds"
   SAKURAI TOSHIO: "Manual of X-ray structural analysis", 1983, SHOKABO CO., LTD.
   STOUTJENSEN: "X-Ray Structure Determination: A Practical Guide", 1968, MACMILLAN CO.
   ATHERTON, E.SHEPPARD, R. C.: "In Solid Phase Peptide Synthesis, A Practical Approach", 1989, IRL PRESS AT OXFORD UNIVERSITY PRES
   BIOORG. MED. CHEM., vol. 5, 1997, pages 1883 - 1891
   "Japanese Pharmacopoeia"
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.